Lactoferrin (LF) is a multifunctional cationic protein (pI 8.2 to 8.9) in mammalian milk. We previously reported that enteric-LF prevented hypercholesterolemia and atherosclerosis in a diet-induced atherosclerosis model using Microminipig TM , although the underlying mechanisms remain unclear. Because LF is assumed to electrostatically interact with bile acids to inhibit intestinal cholesterol absorption, LF could promote cholesterol excretion. In this study, we assessed the interaction between LF and taurocholate in vitro and the effect of LF on cholesterol excretion in rats. The binding rate of taurocholate to LF was significantly higher than that to transferrin (pI 5.2 to 6.3). When rats were administered a high-cholesterol diet (HCD) containing 5% LF, LF was detected using ELISA in the upper small intestine from 7.5 to 60 min after the administration. Rats were fed one of the following diets: Control, HCD, or HCD + 5% LF for 21 days. Fecal neutral steroids and hepatic cholesterol levels in the HCD group were significantly higher than those in the Control group. The addition of LF to a HCD significantly increased fecal neutral steroids levels (22% increase, p < 0.05) and reduced hepatic cholesterol levels (17% decrease, p < 0.05). These parameters were inversely correlated (R = −0.63, p < 0.05). These results suggest that LF promotes cholesterol excretion via interactions with bile acids. 
Atherosclerosis, a well-known risk factor for cardiovascular disease, is characterized by the accumulation of lipids within macrophages, which promote inflammation and the formation of atheroma plaques. The development of atherosclerotic cardiovascular disease is strongly associated with serum levels of low-density lipoprotein cholesterol and has been identified as the primary risk factor for atherosclerotic cardiovascular disease (Choy et al. 2004; members 2014; Roy 2014) . Therefore, it is important to prevent the accumulation of serum low-density lipoprotein cholesterol. The use of functional food factors as dietary supplements that are safe for daily consumption presents an attractive approach to prevent hypercholesterolemia and atherosclerosis.
Lactoferrin (LF) is an iron-binding cationic protein that is abundant in breast milk and plays important roles in many physiological functions by acting as an antibacterial, antiviral, immunostimulatory, and antioxidant, in addition to its potential to prevent cancer (Harmsen et al. 1995; Kozu et al. 2009; Shoji et al. 2007; Tomita et al. 1991; Vogel 2012; Zimecki et al. 1998 ).
And besides these actions, several researchers have reported the beneficial effects of LF on lipid metabolism (Moreno-Navarrete et al. 2009; Morishita et al. 2013; Morishita et al. 2015; Takeuchi et al. 2004; Yagi et al. 2008 ). In accordance with these studies, we found that D r a f t 4 enteric-coated LF significantly reduced areas of visceral fat in a double-blind clinical trial (Ono et al. 2010) . As a possible mechanism, we further reported that LF promoted anti-adipogenic activities of pre-adipocytes derived from rat mesenteric fat tissue and lipolytic activities of mature adipocytes differentiated from preadipocytes (Ikoma-Seki et al. 2015; Ono et al. 2013; Ono et al. 2011 ).
Several beneficial effects of LF on cholesterol-related disorders have also been reported. For example, Takeuchi et al. (2004) reported that LF administration reduced hepatic cholesterol levels in mice. Our group also found that LF ameliorated hypercholesterolemia in mice (Suzuki, N., unpublished reports). We further demonstrated that enteric LF inhibited the development of hypercholesterolemia and atherosclerosis induced by a high-fat and high-cholesterol diet in MicrominipigTM (MMPig) (Morishita et al.2016 ), which has cholesterol profiles similar to those of humans (i.e., dominance of low-density lipoprotein cholesterol rather than high-density lipoprotein cholesterol), unlike rodents (Kawaguchi et al.
2011).
Lowering of cholesterol is considered the primary approach to prevent atherogenesis (Choy et al. 2004; members 2014; Roy 2014) . Cholesterol is absorbed in the small intestine via solubilization with bile acids and uptakes into micelles (Wilson and Rudel 1994 promote the lowering of serum cholesterol levels (Bokura and Kobayashi 2003; Carroll 1991; Mhurchu et al. 2004 ). These food factors are also reported to reduce the micellar solubility of cholesterol and promote fecal cholesterol excretion in cholesterol-fed rats (Gallaher et al. 2000; Liu et al. 2008; Nagaoka et al. 1999) . Shimazaki et al. (1993) reported that the isoelectric point of LF was 8.2 to 8.9, and Baker and Baker (2009) reported that the surface of LF molecules contained notable positively charged regions. These studies suggested that cationic LF electrostatically interacts with anionic bile acids in the small intestine, which may inhibit cholesterol absorption, resulting in the prevention of hypercholesterolemia and atherosclerosis.
However, the effect of LF on cholesterol absorption remains poorly understood. Therefore, the aims of the present study were to assess the interactions between LF and taurocholate in vitro and the effects of LF on cholesterol excretion in rats.
Materials and Methods

Materials
Bovine LF was purchased from FrieslandCampina (Amersfoort, The Netherlands Table 2 .
Effect of LF on fecal neutral steroid excretion in rats
Three groups, Control, HCD, or HCD + LF groups received 8 rats each with matched mean body weights after the acclimation period and each rat was fed the corresponding diet for 21 days. During the experimental period, all rats were allowed free access to diets and water. The feces of each rat were collected on the last 2 days of the experimental period and then lyophilized and stored at −80°C until analysis. On the final day, blood was collected from the abdominal vein under isoflurane anesthesia without starvation. After exsanguination, livers were immediately excised. The serum samples and livers were stored at −80°C until analysis.
Biochemical analysis
Serum levels of total cholesterol and triglyceride were analyzed using the Cholesterol E-test
Wako kit and Triglyceride E-test Wako kit, respectively (Wako Pure Chemical Industries, Ltd.).
Hepatic lipids were extracted with chloroform/methanol (2:1, v/v) according to the method of (Folch et al. 1957 
Quantification of LF in the proximal halves of the small intestine
After acclimation, the rats were fed HCD + LF for 4 days ad libitum and then fasted for 16 h.
After fasting, rats (n = 6) were fed 4 g of HCD + LF at the beginning of a dark period. At 7.5, 15, 30, and 60 min from the beginning of refeeding, the rats were sacrificed under anesthesia and the contents in the proximal halves of the small intestine were collected, according to the methods described by (Ono et al. 2011 ). In the Control group, rats (n = 4) were fed 4 g of HCD and sacrificed under anesthesia at 30 min from the beginning of refeeding. Collected samples were stored at −80°C until analysis. The amount of LF in the small intestine was quantified using an enzyme-linked immunosorbent assay (ELISA; Bethyl Laboratories, Montgomery, TX, USA).
Statistical analysis
Data are presented as means ± standard deviations. Basically, data were compared using
one-way analysis of variance (ANOVA) and the post-hoc Tukey-Kramer test. A probability (p) value of < 0.05 was considered statistically significant. Data were analyzed using JMP software ver. 11.2.0 (SAS Institute, Inc., Cary, NC, USA). Correlations between hepatic cholesterol levels and fecal neutral steroids excretion levels were identified using the Pearson product-moment correlation coefficient.
Results
Interaction between LF and taurocholate in vitro
The interaction between LF and taurocholate, which is a major component of bile acids in rodents (Siow et al. 1991) , was investigated in this study. The percentage of LF-bound taurocholate (unfiltered taurocholate) was significantly increased by the addition of LF at 5 mg/mL or more, as compared with that in the non-additive group. The percentage of LF-bound taurocholate was significantly higher than that of transferrin-bound taurocholate when incubated at the same concentration. The percentage of LF-bound taurocholate at 5 and 10 mg/mL LF were 4.79 ± 1.13% and 12.20 ± 1.35%, respectively.
LF levels in the proximal halves of the small intestine after oral administration
Immunoreactive LF was detected in the content of the proximal intestine from 7.5 to 60 min D r a f t 10 after LF administration (Table 3 ). The maximum amount of LF (1.5 mg/proximal intestine) was detected at 7.5 min and the amount of LF decreased in a time-dependent manner. In the Control group, the amount of LF in the proximal intestine was under the detection limit (< 0.0041 mg/proximal intestine).
Effect of LF on fecal neutral steroid excretion in rats
There was no significant difference in body weight gain or food intake over the 21-day feeding period among the Control, HCD, and HCD + LF groups (Table 4 ). There were no differences in serum concentrations of total cholesterol and triglyceride among the three groups (Table 5 ). The administration of HCD significantly increased hepatic cholesterol levels compared with those in the Control group. The addition of LF to HCD significantly decreased hepatic cholesterol levels compared with those in the HCD group (17% decrease, p = 0.0124). As shown in Table 6 , there were no significant differences in fecal weight among the three groups. The excreted levels of fecal bile acids and fecal neutral steroids in the HCD group were significantly higher than those in the Control group. The addition of LF to HCD had no effect on excreted levels of fecal bile acids, whereas LF significantly increased the excreted levels of fecal neutral steroids compared with those in the HCD group (22% increase, p = 0.0189). LF administration exhibited a significant increase in fecal cholesterol excretion compared with the HCD group (33% increase, D r a f t 11 p = 0.0341) but had no effect on fecal coprostanol excretion. As shown by the data in Fig. 2 , there were significant inverse correlations between hepatic cholesterol levels and excreted levels of fecal neutral steroids (R = −0.63, p < 0.05).
Discussion
In our previous study, LF was administered to MMPigs using enteric capsules to evaluate its potential against hypercholesterolemia and atherosclerosis (Morishita et al. 2016). However, it is difficult to administer enteric LF to rats because there is no commercially available enteric formulation. Therefore, LF was administered to rats in this study by dietary supplementation.
It is well known that the administration of high-cholesterol diet to rats increases the excretion of fecal steroids and induces hepatic cholesterol accumulation. Various researchers have reported that food factors which inhibit cholesterol absorption, such as catechins, dietary fibers, and soy protein, increase fecal steroid excretion, and decrease hepatic cholesterol levels in high-cholesterol diet fed rats (Arjmandi et al. 1992; Gallaher et al. 2000; Kobayashi et al. 2005; Muramatsu et al. 1986; Nagaoka et al. 1999 ). The present study revealed that LF promoted fecal cholesterol excretion in rats fed HCD (Table 6 ), suggesting that LF inhibited cholesterol absorption in the small intestine. The negative correlation between hepatic cholesterol levels and excretion levels of fecal neutral steroids was also observed in this study D r a f t (Fig. 2) . This observation is consistent with the results of previous publication investigating the effect of soy and potato peptide on lipid homeostasis (Liyanage et al. 2009 ). Taken together with our study, it is suggested that the increase in cholesterol excretion led to a reduction in hepatic cholesterol levels. Contrary to the findings of this study, Takeuchi et al. (2004) reported that the administration of 1% LF did not affect fecal cholesterol excretion by mice fed a 1% cholesterol diet. In this study, we administered a diet containing 5% LF and 0.3% cholesterol to rats. Therefore, the difference in fecal cholesterol excretion compared with that in previous studies may be due to differences in experimental conditions, such as animal species and compositions of test diets.
The results of this study showed that LF interacted with taurocholate in vitro (Fig. 1) , whereas LF did not affect the excretion of fecal bile acids (Table 6 ). It is generally recognized that orally administered proteins are hydrolyzed in the gastrointestinal tract. Although LF was detected using ELISA in the proximal region of the rat small intestine in this study (Table 3) , Kuwata et al. (2001) reported that orally administered LF was degraded more intensively in the distal region, where bile acids are reabsorbed, compared with the proximal region of the small intestine. This report suggests that intensively degraded LF might fail to interact with bile acids and allow reabsorption of bile acids in the distal region.
In the small intestine, cholesterol is solubilized in bile acid micelles and diffuses to the D r a f t small intestinal epithelial cells across the unstirred water layer. Subsequently, cholesterol is released from micelles and absorbed into the small intestinal epithelial cells (Wilson and Rudel 1994) . Cholesterol absorption primarily occurs in the proximal region of the small intestine, which has a high expression of the cholesterol transporter Niemann-Pick C1 Like1 (NPC1L1) (Altmann et al. 2004) . In this study, LF was detected in the proximal halves of the small intestine from 7.5 to 60 min after LF administration using ELISA (Table 3) . Previously, we demonstrated that the digestion of LF with trypsin yielded relatively large fragments and digestion with pepsin yielded very small fragments (Ono et al. 2011) . We confirmed that the ELISA kit could detect intact LF and trypsin-degraded LF but not pepsin-degraded LF (data not shown). Therefore, relatively large fragments of LF seemed to reach the proximal regions of the rat small intestine after oral administration. We further demonstrated an interaction between LF and taurocholate in an in vitro study (Fig. 1) . Bile acid-binding food factors such as soy protein are reported to reduce micellar solubility of cholesterol and to suppress intestinal cholesterol absorption (Nagaoka et al. 1999) . Altogether, the present study implies the possibility that the interaction between LF and bile acids lead to the decrease of micellar solubility of cholesterol and the inhibition of intestinal cholesterol absorption. It should be noted that the cationic peptide lactoferricin is produced by pepsin following the oral administration of LF (Tomita et al. 2009 An interaction between LF and taurocholate was observed (Fig. 1) under the similar conditions as a previous report using dietary fibers (Huth et al. 2000) . D r a f t Table 6 . Fecal weight and steroid excretion levels during the last 2 days of the feeding period D r a f t Fig. 1 . Interaction between LF and taurocholate in vitro LF (pI 8.2 to 8.9) or transferrin (pI 5.2 to 6.3) was incubated with 0.5 mg/mL sodium taurocholate in phosphate buffer (pH 6.5) at 37ºC for 2 h. A decrease in taurocholate after ultrafiltration (MWCO 10K) was determined and showed as taurocholate bound (%). Values are expressed as means ± standard deviations (n = 4). Statistical analysis was performed using one-way ANOVA followed by the post-hoc Tukey-Kramer test. Different letters (a, b, c) indicate significant differences between groups (p < 0.05). 
